William Blair Investment Management LLC Boosts Position in Alignment Healthcare, Inc. $ALHC

William Blair Investment Management LLC increased its stake in Alignment Healthcare, Inc. (NASDAQ:ALHC) by 8.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,305,255 shares of the company’s stock after buying an additional 185,303 shares during the period. William Blair Investment Management LLC’s holdings in Alignment Healthcare were worth $45,529,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in ALHC. Wellington Management Group LLP increased its stake in Alignment Healthcare by 167.3% in the 3rd quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock worth $193,516,000 after buying an additional 6,940,277 shares during the period. Invesco Ltd. increased its stake in Alignment Healthcare by 122.3% in the 2nd quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock worth $58,387,000 after buying an additional 2,294,739 shares during the period. Danica Pension Livsforsikringsaktieselskab purchased a new position in Alignment Healthcare in the 4th quarter worth about $39,500,000. Assenagon Asset Management S.A. increased its stake in Alignment Healthcare by 6,708.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,774,975 shares of the company’s stock worth $35,056,000 after buying an additional 1,748,903 shares during the period. Finally, Vanguard Group Inc. increased its stake in Alignment Healthcare by 10.9% in the 4th quarter. Vanguard Group Inc. now owns 15,492,802 shares of the company’s stock worth $305,983,000 after buying an additional 1,524,218 shares during the period. Hedge funds and other institutional investors own 86.19% of the company’s stock.

Insider Transactions at Alignment Healthcare

In other news, CEO John E. Kao sold 298,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $16.89, for a total value of $5,033,220.00. Following the sale, the chief executive officer directly owned 1,508,641 shares in the company, valued at approximately $25,480,946.49. This trade represents a 16.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Dawn Christine Maroney sold 36,749 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $17.84, for a total transaction of $655,602.16. Following the completion of the sale, the president owned 1,058,813 shares in the company, valued at $18,889,223.92. This represents a 3.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,569,859 shares of company stock worth $29,433,158 in the last three months. Insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on the stock. UBS Group raised their price target on shares of Alignment Healthcare from $21.00 to $22.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Wall Street Zen raised shares of Alignment Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings raised shares of Alignment Healthcare from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. Robert W. Baird set a $28.00 target price on shares of Alignment Healthcare in a research report on Friday, January 30th. Finally, JPMorgan Chase & Co. raised their target price on shares of Alignment Healthcare from $23.00 to $26.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Alignment Healthcare currently has an average rating of “Moderate Buy” and an average price target of $24.60.

Alignment Healthcare Stock Performance

NASDAQ ALHC opened at $16.35 on Monday. The company has a debt-to-equity ratio of 1.56, a quick ratio of 1.58 and a current ratio of 1.58. The company has a market capitalization of $3.38 billion, a price-to-earnings ratio of 181.67, a price-to-earnings-growth ratio of 2.29 and a beta of 1.26. The company’s 50-day simple moving average is $18.84 and its two-hundred day simple moving average is $19.43. Alignment Healthcare, Inc. has a one year low of $11.63 and a one year high of $23.87.

Alignment Healthcare (NASDAQ:ALHC) last posted its earnings results on Thursday, April 30th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.22 billion. Alignment Healthcare had a net margin of 0.47% and a return on equity of 11.50%. The company’s revenue for the quarter was up 33.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.05) EPS. Equities analysts forecast that Alignment Healthcare, Inc. will post 0.19 EPS for the current fiscal year.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.